Different benefits of adaptive radiotherapy for different histologies of NSCLC.


Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: Sweden
ID NLM: 8709065

Informations de publication

Date de publication:
Nov 2023
Historique:
medline: 8 11 2023
pubmed: 5 10 2023
entrez: 5 10 2023
Statut: ppublish

Résumé

Adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the most frequent histological subtypes of non-small cell lung cancer (NSCLC). The aim of this study was to investigate how patients with AC and SCC benefit from image-guided adaptive radiotherapy (ART) with tumour match. Consecutive patients diagnosed with AC or SCC of the lung treated with definitive chemo-radiotherapy before and after the implementation of ART and tumour match were retrospectively included for analyses. Data collection included baseline patient and treatment characteristics in addition to clinical data on radiation pneumonitis (RP), failure, and survival. Patients were divided into four categories based on their histology and treatment before ( Median follow-up was 5.7 years for AC and 6.3 years for SCC. Mean lung dose decreased for both histologies with ART, whereas mean heart dose only decreased for patients with AC. Incidences of grade 3 and 5 RP decreased for both histologies with ART. Loco-regional failure (LRF) rates decreased significantly for patients with SCC after ART ( ART and tumour match in the radiotherapeutic treatment of patients with locally advanced NSCLC primarily led to decreased LRF and improved OS for patients with SCC.

Sections du résumé

BACKGROUND UNASSIGNED
Adenocarcinoma (AC) and squamous cell carcinoma (SCC) are the most frequent histological subtypes of non-small cell lung cancer (NSCLC). The aim of this study was to investigate how patients with AC and SCC benefit from image-guided adaptive radiotherapy (ART) with tumour match.
MATERIAL AND METHODS UNASSIGNED
Consecutive patients diagnosed with AC or SCC of the lung treated with definitive chemo-radiotherapy before and after the implementation of ART and tumour match were retrospectively included for analyses. Data collection included baseline patient and treatment characteristics in addition to clinical data on radiation pneumonitis (RP), failure, and survival. Patients were divided into four categories based on their histology and treatment before (
RESULTS UNASSIGNED
Median follow-up was 5.7 years for AC and 6.3 years for SCC. Mean lung dose decreased for both histologies with ART, whereas mean heart dose only decreased for patients with AC. Incidences of grade 3 and 5 RP decreased for both histologies with ART. Loco-regional failure (LRF) rates decreased significantly for patients with SCC after ART (
CONCLUSION UNASSIGNED
ART and tumour match in the radiotherapeutic treatment of patients with locally advanced NSCLC primarily led to decreased LRF and improved OS for patients with SCC.

Identifiants

pubmed: 37796133
doi: 10.1080/0284186X.2023.2260944
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1426-1432

Subventions

Organisme : Cancer Research UK
ID : 28832
Pays : United Kingdom

Auteurs

Marie Tvilum (M)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.

Christina Maria Lutz (CM)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Marianne Marquard Knap (MM)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Lone Hoffmann (L)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Azza Ahmed Khalil (AA)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Marianne Ingerslev Holt (MI)

Department of Clinical Genetics, Sygehus Lillebaelt, Vejle, Denmark.

Maria Kandi (M)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Hjørdis Hjalting Schmidt (HH)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Ane L Appelt (AL)

Leeds Institute of Medical Research at St James's, University of Leeds, Leeds, UK.
Leeds Cancer Centre, St James's University Hospital, Leeds, UK.

Markus Alber (M)

Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Heidelberg Institute for Radiation Oncology (HIRO), Heidelberg University Hospital, Heidelberg, Germany.

Ditte S Møller (DS)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH